{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:42:41Z","timestamp":1790023361906,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Numerous pre-clinical studies and clinical trials demonstrated that induction of antibodies to the \u03b2-amyloid peptide of 42 residues (A\u03b2<jats:sub>42<\/jats:sub>) elicits therapeutic effects in Alzheimer's disease (AD). However, an active vaccination strategy based on full length A\u03b2<jats:sub>42<\/jats:sub> is currently hampered by elicitation of T cell pathological autoreactivity. We attempt to improve vaccine efficacy by creating a novel chimeric flu vaccine expressing the small immunodominant B cell epitope of A\u03b2<jats:sub>42<\/jats:sub>. We hypothesized that in elderly people with pre-existing memory Th cells specific to influenza this dual vaccine will simultaneously boost anti-influenza immunity and induce production of therapeutically active anti-A\u03b2 antibodies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Plasmid-based reverse genetics system was used for the rescue of recombinant influenza virus containing immunodominant B cell epitopes of A\u03b2<jats:sub>42<\/jats:sub> (A\u03b2<jats:sub>1-7\/10<\/jats:sub>).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Two chimeric flu viruses expressing either 7 or 10 aa of A\u03b2<jats:sub>42<\/jats:sub> (flu-A\u03b2<jats:sub>1-7<\/jats:sub> or flu-A\u03b2<jats:sub>1-10<\/jats:sub>) were generated and tested in mice as conventional inactivated vaccines. We demonstrated that this dual vaccine induced therapeutically potent anti-A\u03b2 antibodies and anti-influenza antibodies in mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>We suggest that this strategy might be beneficial for treatment of AD patients as well as for prevention of development of AD pathology in pre-symptomatic individuals while concurrently boosting immunity against influenza.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1479-5876-9-127","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T18:17:49Z","timestamp":1312309069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease"],"prefix":"10.1186","volume":"9","author":[{"given":"Hayk","family":"Davtyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Ghochikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cadagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Petrushina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Movsesyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy A","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G","family":"Agadjanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,1]]},"reference":[{"key":"790_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.med.45.1.435","volume":"45","author":"DL Price","year":"1994","unstructured":"Price DL, Sisodia SS: Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med. 1994, 45: 435-446.","journal-title":"Annu Rev Med"},{"key":"790_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse [see comments]. Nature. 1999, 400: 173-177.","journal-title":"Nature"},{"key":"790_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000, 408: 982-985.","journal-title":"Nature"},{"key":"790_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000, 408: 979-982.","journal-title":"Nature"},{"key":"790_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000, 6: 916-919.","journal-title":"Nat Med"},{"key":"790_CR6","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002, 5: 452-457.","journal-title":"Nat Neurosci"},{"key":"790_CR7","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1523\/JNEUROSCI.1090-04.2004","volume":"24","author":"DM Wilcock","year":"2004","unstructured":"Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D: Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004, 24: 6144-6151.","journal-title":"J Neurosci"},{"key":"790_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JA Nicoll","year":"2003","unstructured":"Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003, 9: 448-452.","journal-title":"Nat Med"},{"key":"790_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1212\/01.WNL.0000148590.39911.DF","volume":"64","author":"E Masliah","year":"2005","unstructured":"Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005, 64: 129-131.","journal-title":"Neurology"},{"key":"790_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E: Antibodies against beta-Amyloid Slow Cognitive Decline in Alzheimer's Disease. Neuron. 2003, 38: 547-554.","journal-title":"Neuron"},{"key":"790_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JA Nicoll","year":"2006","unstructured":"Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D: Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006, 65: 1040-1048.","journal-title":"J Neuropathol Exp Neurol"},{"key":"790_CR12","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005, 64: 1553-1562.","journal-title":"Neurology"},{"key":"790_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW: Long-term effects of Abeta42 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372: 216-223.","journal-title":"Lancet"},{"key":"790_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Rovira MB, Guerra MLS, Rey MJ, Costa-Jussa F: Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004, 14: 11-20.","journal-title":"Brain Pathol"},{"issue":"1","key":"790_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JM, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S: Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003, 61 (1): 46-54.","journal-title":"Neurology"},{"key":"790_CR16","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.2353\/ajpath.2006.060269","volume":"169","author":"RL Patton","year":"2006","unstructured":"Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I: Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006, 169: 1048-1063.","journal-title":"Am J Pathol"},{"key":"790_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S: Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005, 64: 94-101.","journal-title":"Neurology"},{"key":"790_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI11849","volume":"108","author":"B Chackerian","year":"2001","unstructured":"Chackerian B, Lowy DR, Schiller JT: Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest. 2001, 108: 415-423.","journal-title":"J Clin Invest"},{"key":"790_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.autrev.2004.07.004","volume":"3","author":"AK Abbas","year":"2004","unstructured":"Abbas AK, Lohr J, Knoechel B, Nagabhushanam V: T cell tolerance and autoimmunity. Autoimmun Rev. 2004, 3: 471-475.","journal-title":"Autoimmun Rev"},{"key":"790_CR20","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.4049\/jimmunol.174.3.1580","volume":"174","author":"MG Agadjanyan","year":"2005","unstructured":"Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH: Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol. 2005, 174: 1580-1586.","journal-title":"J Immunol"},{"key":"790_CR21","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.vaccine.2005.11.039","volume":"24","author":"A Ghochikyan","year":"2006","unstructured":"Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG: Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine. 2006, 24: 2275-2282.","journal-title":"Vaccine"},{"key":"790_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/gt.2009.140","volume":"17","author":"H Davtyan","year":"2010","unstructured":"Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, Agadjanyan MG, Ghochikyan A: DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther. 2010, 17: 261-271.","journal-title":"Gene Ther"},{"key":"790_CR23","doi-asserted-by":"publisher","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","volume":"27","author":"I Petrushina","year":"2007","unstructured":"Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG: Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble\/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice. J Neurosci. 2007, 27: 12721-12731.","journal-title":"J Neurosci"},{"key":"790_CR24","doi-asserted-by":"crossref","unstructured":"Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe C, Cribbs DH, Agadjanyan MG: Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J Biol Chem. 2007, 22376-22386. 282","DOI":"10.1074\/jbc.M700088200"},{"key":"790_CR25","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1371\/journal.pone.0002124","volume":"3","author":"N Movsesyan","year":"2008","unstructured":"Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG: Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine- a novel immunotherapeutic strategy. PLos ONE. 2008, 3: e21-24.","journal-title":"PLos ONE"},{"key":"790_CR26","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1098\/rstb.2001.0979","volume":"356","author":"JH Schickli","year":"2001","unstructured":"Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P: Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci. 2001, 356: 1965-1973.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"790_CR27","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1128\/JVI.73.11.9679-9682.1999","volume":"73","author":"E Fodor","year":"1999","unstructured":"Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A: Rescue of influenza A virus from recombinant DNA. J Virol. 1999, 73: 9679-9682.","journal-title":"J Virol"},{"key":"790_CR28","doi-asserted-by":"publisher","first-page":"20252","DOI":"10.1074\/jbc.M109.089912","volume":"285","author":"E Nistal-Villan","year":"2010","unstructured":"Nistal-Villan E, Gack MU, Martinez-Delgado G, Maharaj NP, Inn KS, Yang H, Wang R, Aggarwal AK, Jung JU, Garcia-Sastre A: Negative role of RIG-I serine 8 phosphorylation in the regulation of interferon-beta production. J Biol Chem. 2010, 285: 20252-20261.","journal-title":"J Biol Chem"},{"key":"790_CR29","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1016\/j.vaccine.2008.04.073","volume":"26","author":"S Wang","year":"2008","unstructured":"Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S: Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008, 26: 3626-3633.","journal-title":"Vaccine"},{"key":"790_CR30","first-page":"723","volume-title":"DNA Cell Biol","author":"CA Dickey","year":"2001","unstructured":"Dickey CA, Morgan DG, Kudchodkar S, Weiner DB, Bai Y, Cao C, Gordon MN, Ugen KE: Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated beta-amyloid 1-42 peptide. DNA Cell Biol. 2001, 723-729."},{"key":"790_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/1573395054065179","volume":"1","author":"DH Cribbs","year":"2005","unstructured":"Cribbs DH, Agadjanyan MG: Immunotherapy for Alzheimer's Disease: Potential Problems and Possible Solutions. Current Immunology Reviews. 2005, 1: 139-155.","journal-title":"Current Immunology Reviews"},{"key":"790_CR32","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.febslet.2008.12.064","volume":"583","author":"XP Wang","year":"2009","unstructured":"Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, Li JL, Du XT, Lambert MP, Yang SG: Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett. 2009, 583: 579-584.","journal-title":"FEBS Lett"},{"key":"790_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/17460794.2.4.401","volume":"2","author":"L Mart\u00ednez-Sobrido","year":"2007","unstructured":"Mart\u00ednez-Sobrido L, Garcia-Sastre A: Recombinant influenza virus vectors. Future Virology. 2007, 2: 401-416.","journal-title":"Future Virology"},{"key":"790_CR34","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1073\/pnas.0436286100","volume":"100","author":"F Bard","year":"2003","unstructured":"Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K: Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA. 2003, 100: 2023-2028.","journal-title":"Proc Natl Acad Sci USA"},{"key":"790_CR35","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/intimm\/dxg049","volume":"15","author":"DH Cribbs","year":"2003","unstructured":"Cribbs DH, Ghochikyan A, Tran M, Vasilevko V, Petrushina I, Sadzikava N, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol. 2003, 15: 505-514.","journal-title":"Int Immunol"},{"key":"790_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0304-3940(02)01357-5","volume":"338","author":"I Petrushina","year":"2003","unstructured":"Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH: Importance of IgG2c isotype in the immune response to b-amyloid in APP\/Tg mice. Neurosci Letters. 2003, 338: 5-8.","journal-title":"Neurosci Letters"},{"key":"790_CR37","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med. 2002, 8: 1263-1269.","journal-title":"Nat Med"},{"key":"790_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/10445490152717569","volume":"20","author":"CA Lemere","year":"2001","unstructured":"Lemere CA, Maron R, Selkoe DJ, Weiner HL: Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol. 2001, 20: 705-711.","journal-title":"DNA Cell Biol"},{"key":"790_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0304-3940(01)01951-6","volume":"307","author":"T Town","year":"2001","unstructured":"Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M: Characterization of murine immunoglobulin G antibodies agaisnt human amyloid-b 1-42. Neuroscience Letters. 2001, 307: 101-104.","journal-title":"Neuroscience Letters"},{"key":"790_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.20592","volume":"58","author":"M Lee","year":"2005","unstructured":"Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P: Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol. 2005, 58: 430-435.","journal-title":"Ann Neurol"},{"key":"790_CR41","doi-asserted-by":"publisher","first-page":"10273","DOI":"10.1073\/pnas.191118298","volume":"98","author":"A Monsonego","year":"2001","unstructured":"Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL: Immune hyporespobnsivness to amyloid b-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Nat Acad Sci USA. 2001, 98: 10273-10278.","journal-title":"Proc Nat Acad Sci USA"},{"key":"790_CR42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nrn938","volume":"3","author":"D Schenk","year":"2002","unstructured":"Schenk D: Opinion: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002, 3: 824-828.","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 2","key":"790_CR43","doi-asserted-by":"publisher","first-page":"14657","DOI":"10.1073\/pnas.0404866101","volume":"101","author":"DS Gelinas","year":"2004","unstructured":"Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J: Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA. 2004, 101 (Suppl 2): 14657-14662.","journal-title":"Proc Natl Acad Sci USA"},{"key":"790_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/ni0504-460","volume":"5","author":"MM Levine","year":"2004","unstructured":"Levine MM, Sztein MB: Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004, 5: 460-464.","journal-title":"Nat Immunol"},{"key":"790_CR45","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1474-4422(03)00349-1","volume":"2","author":"RC Dodel","year":"2003","unstructured":"Dodel RC, Hampel H, Du Y: Immunotherapy for Alzheimer's disease. Lancet Neurol. 2003, 2: 215-220.","journal-title":"Lancet Neurol"},{"key":"790_CR46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1471-4914(03)00022-4","volume":"9","author":"JC Dodart","year":"2003","unstructured":"Dodart JC, Bales KR, Paul SM: Immunotherapy for Alzheimer's disease: will vaccination work?. Trends Mol Med. 2003, 9: 85-87.","journal-title":"Trends Mol Med"},{"key":"790_CR47","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1126\/science.1088469","volume":"302","author":"A Monsonego","year":"2003","unstructured":"Monsonego A, Weiner HL: Immunotherapeutic approaches to Alzheimer's disease. Science. 2003, 302: 834-838.","journal-title":"Science"},{"key":"790_CR48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00002093-200401000-00008","volume":"18","author":"FL Heppner","year":"2004","unstructured":"Heppner FL, Gandy S, McLaurin J: Current Concepts and Future Prospects for Alzheimer Disease Vaccines. J Alz Dis Ass Disord. 2004, 18: 38-43.","journal-title":"J Alz Dis Ass Disord"},{"key":"790_CR49","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/nature01325","volume":"420","author":"HL Weiner","year":"2002","unstructured":"Weiner HL, Selkoe DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature. 2002, 420: 879-884.","journal-title":"Nature"},{"key":"790_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jnr.10876","volume":"75","author":"O Broytman","year":"2004","unstructured":"Broytman O, Malter JS: Anti-Abeta: The good, the bad, and the unforeseen. J Neurosci Res. 2004, 75: 301-306.","journal-title":"J Neurosci Res"},{"key":"790_CR51","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0169-409X(02)00158-8","volume":"54","author":"DM Holtzman","year":"2002","unstructured":"Holtzman DM, Bales KR, Paul SM, DeMattos RB: Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev. 2002, 54: 1603-1613.","journal-title":"Adv Drug Deliv Rev"},{"key":"790_CR52","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.coi.2004.07.012","volume":"16","author":"D Schenk","year":"2004","unstructured":"Schenk D, Hagen M, Seubert P: Current progress in beta-amyloid immunotherapy. Curr Opin Immunol. 2004, 16: 599-606.","journal-title":"Curr Opin Immunol"},{"key":"790_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/187152709787601830","volume":"8","author":"TE Golde","year":"2009","unstructured":"Golde TE, Das P, Levites Y: Quantitative and mechanistic studies of abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009, 8: 31-49.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"790_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/187152709787601821","volume":"8","author":"D Morgan","year":"2009","unstructured":"Morgan D: The role of microglia in antibody-mediated clearance of amyloid-beta from the brain. CNS Neurol Disord Drug Targets. 2009, 8: 7-15.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"40","key":"790_CR55","doi-asserted-by":"publisher","first-page":"11682","DOI":"10.1021\/bi030100s","volume":"42","author":"DL Miller","year":"2003","unstructured":"Miller DL, Currie JR, Mehta PD, Potemska A, Hwang YW, Wegiel J: Humoral immune response to fibrillar beta-amyloid peptide. Biochemistry. 2003, 42 (40): 11682-11692.","journal-title":"Biochemistry"},{"issue":"3","key":"790_CR56","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI200318104","volume":"112","author":"A Monsonego","year":"2003","unstructured":"Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, Budson AE, Sperling R, Selkoe D, Weiner HL: Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003, 112 (3): 415-422.","journal-title":"J Clin Invest"},{"key":"790_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrneurol.2009.219","volume":"6","author":"CA Lemere","year":"2010","unstructured":"Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nat Rev Neurol. 2010, 6: 108-119.","journal-title":"Nat Rev Neurol"},{"key":"790_CR58","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1016\/j.vaccine.2006.05.059","volume":"24","author":"B Chackerian","year":"2006","unstructured":"Chackerian B, Rangel M, Hunter Z, Peabody DS: Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine. 2006, 24: 6321-6331.","journal-title":"Vaccine"},{"key":"790_CR59","doi-asserted-by":"publisher","first-page":"7613","DOI":"10.4049\/jimmunol.0803366","volume":"182","author":"P Bach","year":"2009","unstructured":"Bach P, Tschape JA, Kopietz F, Braun G, Baade JK, Wiederhold KH, Staufenbiel M, Prinz M, Deller T, Kalinke U: Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. J Immunol. 2009, 182: 7613-7624.","journal-title":"J Immunol"},{"key":"790_CR60","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11481-009-9183-1","volume":"5","author":"QY Li","year":"2010","unstructured":"Li QY, Gordon MN, Chackerian B, Alamed J, Ugen KE, Morgan D: Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. J Neuroimmune Pharmacol. 2010, 5: 133-142.","journal-title":"J Neuroimmune Pharmacol"},{"key":"790_CR61","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.4049\/jimmunol.177.4.2662","volume":"177","author":"E Zamora","year":"2006","unstructured":"Zamora E, Handisurya A, Shafti-Keramat S, Borchelt D, Rudow G, Conant K, Cox C, Troncoso JC, Kirnbauer R: Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol. 2006, 177: 2662-2670.","journal-title":"J Immunol"},{"key":"790_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/icb.2010.134","volume":"89","author":"F Mantile","year":"2011","unstructured":"Mantile F, Basile C, Cicatiello V, De Falco D, Caivano A, De Berardinis P, Prisco A: A multimeric immunogen for the induction of immune memory to beta-amyloid. Immunol Cell Biol. 2011, 89: 604-609.","journal-title":"Immunol Cell Biol"},{"key":"790_CR63","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1515\/BC.2008.064","volume":"389","author":"GT Jennings","year":"2008","unstructured":"Jennings GT, Bachmann MF: The coming of age of virus-like particle vaccines. Biol Chem. 2008, 389: 521-536.","journal-title":"Biol Chem"},{"key":"790_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jalz.2009.05.356","volume":"5","author":"BG Winblad","year":"2009","unstructured":"Winblad BG, Minthon L, Floesser A, Imbert G, Dumortier T, He Y, Maguire P, Karlsson M, Ostlund H, Lundmark J: Results of the first-in-man study with the active Abeta immunotherapy CAD106 in Alzheimer's patients. Alzheimer's & Dementia: Journal of Alzheimer's Association. 2009, 5: 113-114.","journal-title":"Alzheimer's & Dementia: Journal of Alzheimer's Association"},{"key":"790_CR65","volume-title":"Book Active immunization against amyloid: Ab1-6\/Qb (CAD106) removes b-amyloid from the brain, does not induce Ab-reactive T cells and is well tolerated ina first-in-man study in AD (Editor ed.^eds.) City","author":"J-M Orgogozo","year":"2011","unstructured":"Orgogozo J-M, Graf A, Staufenbiel M, Andreasen N, Winblad B: Active immunization against amyloid: Ab1-6\/Qb (CAD106) removes b-amyloid from the brain, does not induce Ab-reactive T cells and is well tolerated ina first-in-man study in AD. Book Active immunization against amyloid: Ab1-6\/Qb (CAD106) removes b-amyloid from the brain, does not induce Ab-reactive T cells and is well tolerated ina first-in-man study in AD (Editor ed.^eds.) City. 2011"},{"key":"790_CR66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0167-7799(98)01192-5","volume":"16","author":"A Garcia-Sastre","year":"1998","unstructured":"Garcia-Sastre A: Negative-strand RNA viruses: applications to biotechnology. Trends Biotechnol. 1998, 16: 230-235.","journal-title":"Trends Biotechnol"},{"key":"790_CR67","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/jvi.66.1.399-404.1992","volume":"66","author":"SQ Li","year":"1992","unstructured":"Li SQ, Schulman JL, Moran T, Bona C, Palese P: Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol. 1992, 66: 399-404.","journal-title":"J Virol"},{"key":"790_CR68","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1128\/jvi.67.11.6659-6666.1993","volume":"67","author":"S Li","year":"1993","unstructured":"Li S, Polonis V, Isobe H, Zaghouani H, Guinea R, Moran T, Bona C, Palese P: Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol. 1993, 67: 6659-6666.","journal-title":"J Virol"},{"key":"790_CR69","doi-asserted-by":"publisher","first-page":"7411","DOI":"10.1128\/JVI.77.13.7411-7424.2003","volume":"77","author":"CL Efferson","year":"2003","unstructured":"Efferson CL, Schickli J, Ko BK, Kawano K, Mouzi S, Palese P, Garcia-Sastre A, Ioannides CG: Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2\/neu proto-oncogene. J Virol. 2003, 77: 7411-7424.","journal-title":"J Virol"},{"key":"790_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/187152709787601849","volume":"8","author":"MG Agadjanyan","year":"2009","unstructured":"Agadjanyan MG, Cribbs DH: Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part I. CNS Neurol Disord Drug Targets. 2009, 8: 1-6.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"790_CR71","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2174\/187152709787847270","volume":"8","author":"DH Cribbs","year":"2009","unstructured":"Cribbs DH, Agadjanyan MG: Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II. CNS Neurol Disord Drug Targets. 2009, 8: 82-87.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"790_CR72","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1001\/archneur.64.3.431","volume":"64","author":"BJ Bacskai","year":"2007","unstructured":"Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST: Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007, 64: 431-434.","journal-title":"Arch Neurol"},{"key":"790_CR73","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","volume":"68","author":"RJ Bateman","year":"2007","unstructured":"Bateman RJ, Wen G, Morris JC, Holtzman DM: Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007, 68: 666-669.","journal-title":"Neurology"},{"key":"790_CR74","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM: Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007, 64: 343-349.","journal-title":"Arch Neurol"},{"key":"790_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG: Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007, 64: 354-362.","journal-title":"Arch Neurol"},{"key":"790_CR76","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ana.21099","volume":"61","author":"JS Kauwe","year":"2007","unstructured":"Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, Fagan AM, Holtzman DM, Morris JC, Goate AM: Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol. 2007, 61: 446-453.","journal-title":"Ann Neurol"},{"key":"790_CR77","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1001\/archneur.64.3.366","volume":"64","author":"AH Simonsen","year":"2007","unstructured":"Simonsen AH, McGuire J, Hansson O, Zetterberg H, Podust VN, Davies HA, Waldemar G, Minthon L, Blennow K: Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol. 2007, 64: 366-370.","journal-title":"Arch Neurol"},{"key":"790_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4049\/jimmunol.169.1.117","volume":"169","author":"HH Hofstetter","year":"2002","unstructured":"Hofstetter HH, Shive CL, Forsthuber TG: Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol. 2002, 169: 117-125.","journal-title":"J Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-9-127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:16:03Z","timestamp":1630512963000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-9-127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":78,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-9-127","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]},"assertion":[{"value":"12 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"127"}}